RhumbLine Advisers
IMNM icon

RhumbLine Advisers’s Immunome IMNM Stock Holding History

RhumbLine Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Buy
132,479
+11,579
+10% +$248K ﹤0.01% 1763
2026
Q1 		$2.64M Buy
120,900
+7,335
+6% +$163K ﹤0.01% 1719
2025
Q4 		$2.44M Buy
113,565
+5,485
+5% +$96.3K ﹤0.01% 1749
2025
Q3 		$1.27M Sell
108,080
-334
-0.3% -$3.32K ﹤0.01% 2124
2025
Q2 		$1.01M Buy
108,414
+19,526
+22% +$160K ﹤0.01% 2246
2025
Q1 		$598K Buy
88,888
+20,721
+30% +$199K ﹤0.01% 2464
2024
Q4 		$724K Sell
68,167
-852
-1% -$10.3K ﹤0.01% 2428
2024
Q3 		$1.01M Buy
69,019
+1,835
+3% +$26.1K ﹤0.01% 2260
2024
Q2 		$813K Buy
+67,184
New +$1.05M ﹤0.01% 2359

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

RhumbLine Advisers's IMNM Position: Q2 2026 in Review

RhumbLine Advisers increased its Immunome (IMNM) stake by 9.6% in Q2 2026, buying an estimated $248K and bringing the position to 132,479 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1763.

RhumbLine Advisers first reported a position in IMNM in Q2 2024 and has held it in 9 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • RhumbLine Advisers held 132,479 shares of Immunome worth $2.81M as of Q2 2026.
  • RhumbLine Advisers bought 11,579 Immunome shares in Q2 2026, an estimated $248K.
  • Immunome made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1763 holding.
  • RhumbLine Advisers first reported a position in Immunome in Q2 2024 and has held it in 9 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.